DE69936248D1 - Verwendung von tcf-ii zur behandlung oder vorbeugung von sepsis - Google Patents

Verwendung von tcf-ii zur behandlung oder vorbeugung von sepsis

Info

Publication number
DE69936248D1
DE69936248D1 DE69936248T DE69936248T DE69936248D1 DE 69936248 D1 DE69936248 D1 DE 69936248D1 DE 69936248 T DE69936248 T DE 69936248T DE 69936248 T DE69936248 T DE 69936248T DE 69936248 D1 DE69936248 D1 DE 69936248D1
Authority
DE
Germany
Prior art keywords
tcf
sepsis
preventives
treat
remedies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69936248T
Other languages
English (en)
Other versions
DE69936248T2 (de
Inventor
Tohru Tani
Hiroyuki Kondo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Atlas Pharmaceuticals Inc Sunnyvale Calif Us
Original Assignee
Daiichi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Pharmaceutical Co Ltd filed Critical Daiichi Pharmaceutical Co Ltd
Publication of DE69936248D1 publication Critical patent/DE69936248D1/de
Application granted granted Critical
Publication of DE69936248T2 publication Critical patent/DE69936248T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Water Treatment By Sorption (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69936248T 1998-03-19 1999-03-19 Verwendung von tcf-ii zur behandlung oder vorbeugung von sepsis Expired - Fee Related DE69936248T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP10070914A JPH11269091A (ja) 1998-03-19 1998-03-19 敗血症予防及び／又は治療剤
JP7091498 1998-03-19
PCT/JP1999/001373 WO1999047155A1 (fr) 1998-03-19 1999-03-19 Medicaments preventifs et/ou curatifs contre la septicemie

Publications (2)

Publication Number Publication Date
DE69936248D1 true DE69936248D1 (de) 2007-07-19
DE69936248T2 DE69936248T2 (de) 2008-01-31

Family

ID=13445266

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69936248T Expired - Fee Related DE69936248T2 (de) 1998-03-19 1999-03-19 Verwendung von tcf-ii zur behandlung oder vorbeugung von sepsis

Country Status (13)

Country Link
US (1) US20060251615A1 (de)
EP (1) EP0982037B1 (de)
JP (1) JPH11269091A (de)
KR (1) KR100572044B1 (de)
AT (1) ATE363913T1 (de)
AU (1) AU753198B2 (de)
CA (1) CA2288881A1 (de)
DE (1) DE69936248T2 (de)
DK (1) DK0982037T3 (de)
ES (1) ES2288014T3 (de)
TW (1) TW518229B (de)
WO (1) WO1999047155A1 (de)
ZA (1) ZA997352B (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4006058B2 (ja) 1997-03-11 2007-11-14 第一三共株式会社 多臓器不全予防及び／又は治療剤
CA2253629A1 (en) 1997-03-14 1998-09-24 Snow Brand Milk Products Co., Ltd. Agent for preventing and/or treating cachexia

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ232813A (en) * 1989-03-10 1992-08-26 Snow Brand Milk Products Co Ltd Human fibroblast glycoprotein, cell differentiation, blood vessel endothelial cell growth factor, cellular immunology inforcing factor of 78 or 74 thousand daltons plus or minus two thousand daltons
KR100260964B1 (ko) * 1992-07-16 2000-07-01 쇼노 카츄야 Tcf-ii를 유효성분으로 하는 혈액응고 정상화제
DE69334281D1 (de) * 1992-07-16 2009-05-28 Daiichi Sankyo Co Ltd TCF-II enthaltende medizinische Zusammensetzung

Also Published As

Publication number Publication date
CA2288881A1 (en) 1999-09-23
EP0982037B1 (de) 2007-06-06
AU2853699A (en) 1999-10-11
KR20010012687A (ko) 2001-02-26
JPH11269091A (ja) 1999-10-05
EP0982037A1 (de) 2000-03-01
EP0982037A4 (de) 2004-10-13
KR100572044B1 (ko) 2006-04-17
DE69936248T2 (de) 2008-01-31
TW518229B (en) 2003-01-21
ATE363913T1 (de) 2007-06-15
DK0982037T3 (da) 2007-10-08
AU753198B2 (en) 2002-10-10
US20060251615A1 (en) 2006-11-09
WO1999047155A1 (fr) 1999-09-23
ES2288014T3 (es) 2007-12-16
ZA997352B (en) 2000-05-29

Similar Documents

Publication Publication Date Title
NO20004911D0 (no) Antitumormiddel
YU21401A (sh) Tetrahidropiridoetri
EA200600618A1 (ru) Применение эффекторов глутаминил- и глутаматциклаз
ATE397580T1 (de) Verwendung von ingenan derivaten zur herstellung eines medikaments zur krebsbekämpfung
DE59903921D1 (de) Indolderivate und deren verwendung zur behandlung von malignen und anderen, auf pathologischen zellproliferationen beruhenden erkrankungen
TR200100874T2 (tr) Simetrik ve simetrik olmayan sübstitüe edilmiş difenil üreler kullanılarak raf kinazın inhibe edilmesi
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
CY2538B1 (en) Tetrahydropyrido compounds
DE69927688D1 (de) Antivirales Mittel in Kombination mit Strahlentherapie zur Verwendung in der Behandlung von Krebs
FR2751879B1 (fr) Composition pharmaceutique contre les tumeurs et infections a papillomavirus
ATE386742T1 (de) Imidazonaphthyridine
ATE222119T1 (de) Verwendung von erythropoietin zur behandlung von multiple myelom
WO2003017939A3 (en) Piperazinone compounds as anti-tumor and anti-cancer agents and methods of treatment
TR199801732T2 (xx) Yeni taksoitler, bunlar�n haz�rlanmalar� ve ila� bile�imleri.
PT1140113E (pt) Utilizacao de bisfosfonatos para profilaxia e tratamento de processos infecciosos
ATE363913T1 (de) Verwendung von tcf-ii zur behandlung oder vorbeugung von sepsis
DE3784768D1 (de) Verwendung von zusammensetzungen auf basis von crotoxin, zur herstellung von medikamenten zur behandlung von carcinomen.
JPS5217946A (en) Underlay for shoes sterilized by copper
IL148336A0 (en) Medicaments that contain xenogenic oligo-or/and polyribonucleotides
ATE86863T1 (de) Verwendung von zusammensetzungen auf basis von crotoxin, zur herstellung von medikamenten zur behandlung von carcinomen.
HK1045253A1 (en) Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis
ATE95062T1 (de) Zusammensetzung zur behandlung von krebs, gekennzeichnet durch ueberexpression des c-fmsproto-onkogens.
BG105763A (en) Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: ATLAS PHARMACEUTICALS, INC., SUNNYVALE, CALIF., US

8339 Ceased/non-payment of the annual fee